FDA Expands Approval of Drug to Stave Off Type 1 Diabetes
The FDA expanded the approval for teplizumab (Tzield), a biologic that delays the progression of preclinical type 1 diabetes to the symptomatic form, to include treatment in kids as young…
The FDA expanded the approval for teplizumab (Tzield), a biologic that delays the progression of preclinical type 1 diabetes to the symptomatic form, to include treatment in kids as young…
Breakthrough T1DTzield approved for children ages one and older in stage 2 T1DThe U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type…
The U.S. Food & Drug Administration announced that a glucose meter (a.k.a. a blood sugar meter) company is issuing an important correction for its blood glucose monitoring system.True Metrix is…
There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay…
A person wears the MiniMed 780G pump on the hip with the Instinct sensor on the arm. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) today announced three U.S. milestones expanding access…
GALWAY, Ireland, Feb. 22026 /PRNewswire/ — Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living…
The US Food and Drug Administration (FDA) has approved an updated label for insulin human (Afrezza) inhalation powder, which provides guidance for starting dosages when switching from multiple daily injections…
MiniMed Go™ is the first and only smart MDI system that automatically integrates insulin dosing and glucose data in a single app to provide empowering insights for individuals on multiple…
The US Food and Drug Administration has accepted for Priority Review a supplemental biologic license application for Tzield (teplizumab-mzwv) to expand its age indication to include children as young as…
The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older…